Drugs Made In America Acquisition Corp. Rights operates as a blank check company. Now — the numbers.
There is not enough trading history here to call this an established business.
If every debt were paid off today, $6K would still be left — though next to the size of the company that is a thin cushion.
The market pays 48.4× for every dollar this company earns in a year — a price that already assumes things go well.
Against companies in its own sector, it looks cheaper than 24% of them.
No analyst target is on record for this company.
Executives buying with their own money is usually read as confidence in the company’s future.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
The stock has been running stronger than the market lately.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
Growth: Sales growth trails the sector average.
The stock trades 45% below its peak. The market has trimmed its expectations for the company.
Over the last 12 months, company executives reported 12 buys and 4 sells. Management buying with its own money is usually read as a good sign.
The stock sits at $0.13. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
This stock swings about 3.9 times as much as the market average. Big rallies — and big drops — can both happen fast.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the growth trend, earnings execution, the revenue breakdown.